Revolution Medicines (NASDAQ:RVMD) COO Margaret Horn Sells 29,600 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) COO Margaret Horn sold 29,600 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $160.12, for a total transaction of $4,739,552.00. Following the sale, the chief operating officer directly owned 154,647 shares of the company’s stock, valued at $24,762,077.64. The trade was a 16.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Revolution Medicines Price Performance

Revolution Medicines stock opened at $157.77 on Thursday. Revolution Medicines, Inc. has a 52-week low of $34.00 and a 52-week high of $166.50. The firm has a market capitalization of $33.54 billion, a price-to-earnings ratio of -22.32 and a beta of 1.40. The company has a fifty day simple moving average of $144.38 and a 200-day simple moving average of $112.39. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.19.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, May 6th. The company reported ($2.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.83) by ($0.46). During the same period last year, the firm earned ($1.13) EPS. On average, equities analysts anticipate that Revolution Medicines, Inc. will post -7.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Revolution Medicines

A number of hedge funds have recently modified their holdings of the company. Meeder Advisory Services Inc. grew its holdings in shares of Revolution Medicines by 3.0% in the first quarter. Meeder Advisory Services Inc. now owns 4,126 shares of the company’s stock valued at $401,000 after purchasing an additional 120 shares during the period. PNC Financial Services Group Inc. grew its holdings in shares of Revolution Medicines by 1.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 10,066 shares of the company’s stock valued at $802,000 after purchasing an additional 125 shares during the period. Deutsche Bank AG grew its holdings in shares of Revolution Medicines by 0.4% in the fourth quarter. Deutsche Bank AG now owns 32,217 shares of the company’s stock valued at $2,566,000 after purchasing an additional 130 shares during the period. Signaturefd LLC grew its holdings in shares of Revolution Medicines by 33.1% in the fourth quarter. Signaturefd LLC now owns 656 shares of the company’s stock valued at $52,000 after purchasing an additional 163 shares during the period. Finally, Allworth Financial LP grew its holdings in shares of Revolution Medicines by 57.2% in the fourth quarter. Allworth Financial LP now owns 577 shares of the company’s stock valued at $46,000 after purchasing an additional 210 shares during the period. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on RVMD shares. UBS Group started coverage on shares of Revolution Medicines in a report on Friday, February 27th. They set a “buy” rating for the company. Stifel Nicolaus reaffirmed a “buy” rating on shares of Revolution Medicines in a report on Monday, April 20th. Sanford C. Bernstein started coverage on shares of Revolution Medicines in a report on Thursday, May 21st. They set a “market perform” rating and a $151.00 target price for the company. Jefferies Financial Group started coverage on shares of Revolution Medicines in a report on Monday, March 16th. They set a “buy” rating for the company. Finally, Royal Bank Of Canada upped their target price on shares of Revolution Medicines from $165.00 to $182.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Three research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $123.72.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.